Open Actively Recruiting

A Vaccine (Neoantigen-Targeted ppDC) for the Treatment of H3 G34-mutant Diffuse Hemispheric Glioma

About

Brief Summary
Primary Purpose
Treatment
Study Type
Interventional
Phase
Phase 1 (Cancer Control)

Eligibility

Gender
All
Healthy Volunteers
No
Minimum Age
18 Years
Maximum Age
50 Years

Inclusion Criteria:

Exclusion Criteria:

Join this Trial

Share:
Study Stats
Protocol No.
23-001700
Category
Brain Cancer
Contact
Adreanne Rivera
Location
  • UCLA Westwood
For Providers
NCT No.
NCT06342908
For detailed technical eligibility, visit ClinicalTrials.gov.